Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 24;11(9):2368.
doi: 10.3390/biomedicines11092368.

Chronic Kidney Disease Has No Impact on Tear Film Substance P Concentration in Type 2 Diabetes

Affiliations

Chronic Kidney Disease Has No Impact on Tear Film Substance P Concentration in Type 2 Diabetes

Kofi Asiedu et al. Biomedicines. .

Abstract

Purpose: The study aimed to ascertain the potential effects of chronic kidney disease (CKD) on substance P concentration in the tear film of people with type 2 diabetes.

Methods: Participants were classified into two groups: type 2 diabetes with concurrent chronic kidney disease (T2DM-CKD (n = 25)) and type 2 diabetes without chronic kidney disease (T2DM-no CKD (n = 25)). Ocular surface discomfort assessment, flush tear collection, in-vivo corneal confocal microscopy, and peripheral neuropathy assessment were conducted. Enzyme-linked immunosorbent assays were utilized to ascertain the levels of tear film substance P in collected flush tears. Correlation analysis, hierarchical multiple linear regression analysis, and t-tests or Mann-Whitney U tests were used in the analysis of data for two-group comparisons.

Results: There was no substantial difference between the T2DM-CKD and T2DM-no CKD groups for tear film substance P concentration (4.4 (0.2-50.4) and 5.9 (0.2-47.2) ng/mL, respectively; p = 0.54). No difference was observed in tear film substance P concentration between the low-severity peripheral neuropathy and high-severity peripheral neuropathy groups (4.4 (0.2-50.4) and 3.3 (0.3-40.7) ng/mL, respectively; p = 0.80). Corneal nerve fiber length (9.8 ± 4.6 and 12.4 ± 3.8 mm/mm2, respectively; p = 0.04) and corneal nerve fiber density (14.7 ± 8.5 and 21.1 ± 7.0 no/mm2, respectively; p < 0.01) were reduced significantly in the T2DM-CKD group compared to the T2DM-no CKD group. There were significant differences in corneal nerve fiber density (21.0 ± 8.1 and 15.8 ± 7.7 no/mm2, respectively; p = 0.04) and corneal nerve fiber length (12.9 ± 4.2 and 9.7 ± 3.8 mm/mm2, respectively; p = 0.03) between the low- and high-severity peripheral neuropathy groups.

Conclusion: In conclusion, no significant difference in tear film substance P concentration was observed between type 2 diabetes with and without CKD. Corneal nerve loss, however, was more significant in type 2 diabetes with chronic kidney disease compared to type 2 diabetes alone, indicating that corneal nerve morphological measures could serve greater utility as a tool to detect neuropathy and nephropathy-related corneal nerve changes.

Keywords: chronic kidney disease; cornea; diabetic neuropathy; peripheral neuropathy; substance p.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Showing central and inferior whorl images of T2DM-no CKD (A,C) and T2DM-CKD (B,D) demonstrating corneal nerve loss in T2DM-CKD compared to T2DM-no CKD.

Similar articles

Cited by

References

    1. Arnold R., Pianta T.J., Issar T., Kirby A., Scales C.M., Kwai N.C., Endre Z., Krishnan A.V. Peripheral neuropathy: An important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease. Nephrol. Dial. Transplant. 2022;37:713–719. doi: 10.1093/ndt/gfab043. - DOI - PubMed
    1. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., Lauria G., Malik R.A., Spallone V., Vinik A. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285. doi: 10.2337/dc10-1303. - DOI - PMC - PubMed
    1. Asiedu K., Markoulli M., Tummanapalli S., Chiang J., Alotaibi S., Wang L., Dhanapalaratnam R., Kwai N., Poynten A., Krishnan A. Impact of Chronic Kidney Disease on Corneal Neuroimmune Features in Type 2 Diabetes. J. Clin. Med. 2022;12:16. doi: 10.3390/jcm12010016. - DOI - PMC - PubMed
    1. Sabatino F., Di Zazzo A., De Simone L., Bonini S. The intriguing role of neuropeptides at the ocular surface. Ocul. Surf. 2017;15:2–14. doi: 10.1016/j.jtos.2016.10.003. - DOI - PubMed
    1. Lasagni Vitar R.M., Rama P., Ferrari G. The two-faced effects of nerves and neuropeptides in corneal diseases. Prog. Retin Eye Res. 2022;86:100974. doi: 10.1016/j.preteyeres.2021.100974. - DOI - PubMed

LinkOut - more resources